341 related articles for article (PubMed ID: 29122306)
1. Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Roux A; Caire F; Guyotat J; Menei P; Metellus P; Pallud J;
Neurochirurgie; 2017 Dec; 63(6):433-443. PubMed ID: 29122306
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
3. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Noël G; Schott R; Froelich S; Gaub MP; Boyer P; Fischer-Lokou D; Dufour P; Kehrli P; Maitrot D
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):749-55. PubMed ID: 21300471
[TBL] [Abstract][Full Text] [Related]
4. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
5. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
6. Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice.
Roux A; Peeters S; Zanello M; Bou Nassif R; Abi Lahoud G; Dezamis E; Parraga E; Lechapt-Zalcmann E; Dhermain F; Dumont S; Louvel G; Chretien F; Sauvageon X; Devaux B; Oppenheim C; Pallud J
J Neurooncol; 2017 Oct; 135(1):83-92. PubMed ID: 28669011
[TBL] [Abstract][Full Text] [Related]
7. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
8. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Lin SH; Kleinberg LR
Expert Rev Anticancer Ther; 2008 Mar; 8(3):343-59. PubMed ID: 18366283
[TBL] [Abstract][Full Text] [Related]
9. Importance and accuracy of intraoperative frozen section diagnosis of the resection margin for effective carmustine wafer implantation.
Asano K; Kurose A; Kamataki A; Kato N; Ogawa K; Katayama K; Kakuta K; Fumoto T; Ohkuma H
Brain Tumor Pathol; 2018 Jul; 35(3):131-140. PubMed ID: 29948295
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Recurrence After Resection of Malignant Gliomas With BCNU Wafer Implants: Retrospective Review in a Single Institution.
Shimato S; Nishizawa T; Ohshima T; Imai T; Goto S; Yamamoto T; Kato K
World Neurosurg; 2016 Jun; 90():340-347. PubMed ID: 26960286
[TBL] [Abstract][Full Text] [Related]
11. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
Pallud J; Audureau E; Noel G; Corns R; Lechapt-Zalcman E; Duntze J; Pavlov V; Guyotat J; Hieu PD; Le Reste PJ; Faillot T; Litre CF; Desse N; Petit A; Emery E; Voirin J; Peltier J; Caire F; Vignes JR; Barat JL; Langlois O; Dezamis E; Parraga E; Zanello M; Nader E; Lefranc M; Bauchet L; Devaux B; Menei P; Metellus P;
Neuro Oncol; 2015 Dec; 17(12):1609-19. PubMed ID: 26185110
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Samis Zella MA; Wallocha M; Slotty PJ; Isik G; Hänggi D; Schroeteler J; Ewelt C; Steiger HJ; Sabel M
Acta Neurochir (Wien); 2014 Feb; 156(2):313-23. PubMed ID: 24287680
[TBL] [Abstract][Full Text] [Related]
14. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
[TBL] [Abstract][Full Text] [Related]
15. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
[TBL] [Abstract][Full Text] [Related]
16. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Duntze J; Litré CF; Eap C; Théret E; Debreuve A; Jovenin N; Lechapt-Zalcman E; Metellus P; Colin P; Guillamo JS; Emery E; Menei P; Rousseaux P; Peruzzi P
Ann Surg Oncol; 2013 Jun; 20(6):2065-72. PubMed ID: 23212763
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Menei P; Metellus P; Parot-Schinkel E; Loiseau H; Capelle L; Jacquet G; Guyotat J;
Ann Surg Oncol; 2010 Jul; 17(7):1740-6. PubMed ID: 20443147
[TBL] [Abstract][Full Text] [Related]
18. The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Gutenberg A; Lumenta CB; Braunsdorf WE; Sabel M; Mehdorn HM; Westphal M; Giese A
J Neurooncol; 2013 Jun; 113(2):163-74. PubMed ID: 23535992
[TBL] [Abstract][Full Text] [Related]
19. BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.
Burri SH; Prabhu RS; Sumrall AL; Brick W; Blaker BD; Heideman BE; Boltes P; Kelly R; Symanowski JT; Wiggins WF; Ashby L; Norton HJ; Judy K; Asher AL
J Neurooncol; 2015 Jun; 123(2):259-66. PubMed ID: 25947286
[TBL] [Abstract][Full Text] [Related]
20. Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series.
Della Puppa A; Rossetto M; Ciccarino P; Denaro L; Rotilio A; d'Avella D; Scienza R
World Neurosurg; 2011; 76(1-2):156-9; discussion 67-8. PubMed ID: 21839967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
